Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLE-22: Nadofaragene Firadenovec Alone or With Chemotherapy in BCG-Unresponsive NMIBC
NCT06545955Phase 3Recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 8
01
Overview
A Phase 3 trial of nadofaragene firadenovec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ferring Pharmaceuticals. Started Oct 2024; status: recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06545955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545955.